Non-Current Assets
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments
Edwards Lifesciences Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 12.9% to $7.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.4%, from $6.20M to $7.90M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
An increase indicates deteriorating performance or valuation write-downs in the private equity or venture portfolio.
Detailed definition
The cumulative amount of downward fair value adjustments recognized for equity securities that lack a readily determinab...
Peer comparison
Standard for firms with significant private equity or venture capital exposure.
Metric ID:
equity_securities_no_fv_downward_adjHistorical Data
8 periods
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $87.60M | $5.50M | $5.50M | $104.90M | $6.20M | $6.20M | $7.00M | $7.90M |
| QoQ Change | — | -93.7% | +0.0% | >999% | -94.1% | +0.0% | +12.9% | +12.9% |
| YoY Change | — | — | — | — | +12.7% | +12.7% | -93.3% | +27.4% |
Range$5.50M – $104.90M
CAGR-74.7%
Avg YoY Growth-10.1%
Median YoY Growth+12.7%
Current Streak3 quarters growth
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's equity securities without readily determinable fair value - cumulative downward adjustments?
- Edwards Lifesciences (EW) reported equity securities without readily determinable fair value - cumulative downward adjustments of $7.90M in Q1 2026.
- How has Edwards Lifesciences's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
- Edwards Lifesciences's equity securities without readily determinable fair value - cumulative downward adjustments increased by 27.4% year-over-year, from $6.20M to $7.90M.
- What does equity securities without readily determinable fair value - cumulative downward adjustments mean?
- Total value lost on private or hard-to-value equity investments.